# Highlights of This Issue 273

## SPECIAL FEATURES

### CCR Translations

**Stressing the Development of Small Molecules Targeting HSP90**
Len Neckers and Jane B. Trepel
See related article, p. 445

**Pertuzumab Protects the Achilles’ Heel of Trastuzumab—Emtansine**
William R. Gwin and Neil L. Spector
See related article, p. 456

### CCR Perspectives in Drug Approval

**Predictive Value of Phase I Trials for Safety in Later Trials and Final Approved Dose: Analysis of 61 Approved Cancer Drugs**
Denis L. Jardim, Kenneth R. Hess, Patricia LoRusso, Razelle Kurzrock, and David S. Hong

### Molecular Pathways

**Molecular Pathways: Targeting Inhibitor of Apoptosis Proteins in Cancer—From Molecular Mechanism to Therapeutic Application**
Simone Fulda

**Molecular Pathways: Transcription Factories and Chromosomal Translocations**
Cameron S. Osborne

### Reviews

**“Quitting Smoking Will Benefit Your Health”: The Evolution of Clinician Messaging to Encourage Tobacco Cessation**
Benjamin A. Toll, Alana M. Rojewski, Lindsay R. Duncan, Amy E. Latimer-Cheung, Lisa M. Fucito, Julie L. Boyer, Stephanie S. O’Malley, Peter Salovey, and Roy S. Herbst

**Deep Molecular Response in Chronic Myeloid Leukemia: The New Goal of Therapy?**
François-Xavier Mahon and Gabriel Etienne

## HUMAN CANCER BIOLOGY

### 323 IgG-Switched CLL Has a Distinct Immunogenetic Signature from the Common MD Variant: Ontogenetic Implications
Anna Vardi, Andreas Agathangeli, Lesley-Ann Sutton, Maria Chatzouli, Lydia Scarfò, Larry Mansouri, Vassiliki Douka, Achilles Anagnostopoulos, Nikos Darzentas, Richard Rosenquist, Paolo Chia, Chrysoula Belesi, and Kostas Stamatopoulos

### 331 Tumor-Reactive CD8⁺ T Cells in Metastatic Gastrointestinal Cancer Refractory to Chemotherapy
Simon Turcotte, Alena Gros, Eric Tran, Chyi-Chia R. Lee, John R. Wunderlich, Paul F. Robbins, and Steven A. Rosenberg

### 344 Altered Microenvironment Promotes Progression of Preinvasive Breast Cancer: Myoepithelial Expression of αvβ6 Integrin in DCIS Identifies High-risk Patients and Predicts Recurrence

### 358 The Activation of the WNT Signaling Pathway Is a Hallmark in Neurofibromatosis Type 1 Tumorigenesis

### 372 Oncogenic Function of SCCRO5/DCUN1D5 Requires Its Neddylation E3 Activity and Nuclear Localization
Claire C. Bommelje, Viola B. Weeda, Guochang Huang, Kushyap Shah, Sarina Rains, Elizabeth Bass, Manish Shaha, Mithat Gonen, Ronald Ghosein, Suresh Y. Ramanathan, and Bhuvanesh Singh
## CANCER THERAPY: PRECLINICAL

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>382</td>
<td>Integrative Genomic Analysis of Temozolomide Resistance in Diffuse Large B-Cell Lymphoma</td>
<td>Violetta V. Leshchenko, Pei-Yu Kuo, Zewei Jiang, Venu K. Thirukonda, and Samir Parekh</td>
</tr>
<tr>
<td>393</td>
<td>Antitumoral Activity of Lenalidomide in <em>In Vitro</em> and <em>In Vivo</em> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27KIP1 Complexes</td>
<td>Alexandra Moros, Sophie Bustany, Julie Cahu, Ilfignia Saborit-Villarroya, Antonio Martínez, Dolors Colomer, Brigitte Sola, and Gaeł Roué</td>
</tr>
<tr>
<td>404</td>
<td>Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations</td>
<td>Evita M. Lindholm, Marit Krohn, Sergio Iadevaia, Alexandr Kristian, Gordon B. Mills, Gunhild M. Mælandsmo, and Olav Engebraaten</td>
</tr>
</tbody>
</table>

## IMAGING, DIAGNOSIS, PROGNOSIS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>425</td>
<td>Prognostic Relevance of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow of Patients with Squamous Cell Carcinoma of the Oral Cavity</td>
<td>Alexander Gröbe, Marco Blessmann, Henning Hanken, Reinhard E. Friedrich, Gerhard Schön, Johannes Wilker, Katharina E. Effenberger, Lan Kluwe, Max Heiland, Klaus Pantel, and Sabine Riethdorf</td>
</tr>
<tr>
<td>434</td>
<td>Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer</td>
<td>John R. Webb, Katy Milne, Peter Watson, Ronald J. deLeeuw, and Brad H. Nelson</td>
</tr>
</tbody>
</table>

## CANCER THERAPY: CLINICAL

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>445</td>
<td>A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors</td>
<td>Muhammad Wasif Saif, Chris Takimoto, Monica Mita, Udai Banerji, Nicole Lamanna, Januario Castro, Susan O’Brien, Christopher Stogard, and Daniel Von Hoff</td>
</tr>
<tr>
<td>469</td>
<td>The High-Affinity CXCR4 Antagonist BKT140 is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma</td>
<td>Amnon Peled, Michal Abraham, Irit Avivi, Jacob M. Rowe, Katia Beider, Hanna Wald, Lena Tionkin, Lena Ribakovskiy, Yossi Riback, Yaron Ramati, Sigal Aviel, Ethan Galun, Howard Laurence Shaw, Orly Eizenberg, Izhard Hardan, Avichai Shimoni, and Amon Nagler</td>
</tr>
</tbody>
</table>
Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up
Selma Ugurel, Thomas Mentzel, Jochen Utikal, Peter Helmhold, Peter Mohr, Claudia Pföhler, Meinhard Schiller, Axel Hauschild, Rüdiger Hein, Eckhardt Kämpgen, Ivonne Kellner, Martin Leverkus, Jürgen C. Becker, Philip Ströbel, and Dirk Schadendorf

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
Aleix Prat, Giampaolo Bianchini, Marlene Thomas, Anton Belousov, Maggie C.U. Cheang, Astrid Koehler, Patricia Gómez, Vladimir Semiglazov, Wolfgang Eiermann, Sergei Tjulandin, Mikhail Byakhow, Begoña Bermejo, Milvia Zambetti, Federico Vazquez, Luca Gianni, and José Baselga

ABOUT THE COVER
The cover shows a section of a lymph node biopsy from a patient with mantle cell lymphoma. Hematoxylin and eosin staining shows typical monomorphous small-to-medium-sized lymphoid cells with irregular nuclei. For details, see the article by Moros and colleagues on page 393 of this issue.
Clinical Cancer Research

20 (2)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/20/2

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.